Sold PDEX at $27.42. Current SellAt price $27.25. Current market $26.78. Bought at an average of $29.18. PDEX no longer qualifies as a SuperGrowth MultiBagger due to weak recent results.
Bought CYRX at $63.87. Algo indicated BuyAt of $64.10. Current market $65.92.
Subscribers receive emails when BuyAt or SellAt levels are achieved, and have access to a Forum were trades are recorded in real time. Subscribers can also opt-in to auto-generated emails when BuyAt and SellAt levels are reached.
Chart Of The Day: CryoPort (CYRX)
A logistics business, servicing CAR-T and gene-based therapy innovators. Provides strict temperature-controlled transport of biological specimens to ensure their livelihood, efficacy, and safety. Three business segments: biopharma, assisted-reproduction, and animal health.
Platform includes the storage medium, the end to end logistics platform, and an integrated cloud-based IT layer. This tech layer provides the end-customer a way to order, track, and manage shipments through Cryoport. Cryoport offers investors a way to play the cell therapy boom without taking direct clinical development risk. In general, cell therapies are a new treatment paradigm that is quickly gaining traction ever since the first major therapies (Yescarta and Kymirah) were approved. According to Deloitte, the overall cell and gene therapy market is expected to grow from $1B in 2018 to $12B in 2025, which translates to over a 36% CAGR.
We follow closely the positions of the ten growth fund managers with the strongest ten year records (“The Master Growth Investors”). CYRX is held by Master Growth Investor Lord Abbett Micro Cap Growth.
Read more here.
- BuyAt $64.10.
- SellAt $76.22.
- Current market $65.90.
CYRX Algo results over the last 12 months:
- Fifteen purchases, fourteen sales.
- Average purchase at $31.65; average sale of $37.76.
- Average return per transaction of 19.3%.
- Average holding period 12 days.
- Annualized return 559.8%.
Risk Research Inc. provides research tools to professional investors based on proprietary AI software. Our software is also available, customized to client specifications, on a monthly rental basis.
Analyst's Disclosure: I am/we are long CYRX.
We offer this research as insight into what we do in our own portfolio rather than as a recommendation or offer to buy or sell securities. This research should not be your sole source of information. It is based on probabilities, not certainties.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.